Anvion Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-07.
Anvion Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 7, 2026. The filing reports $100K sold. Its industry group is Pharmaceuticals. It names Larry Braga (Chief Executive Officer and Secretary), Kevin Ernst (Chief Financial Officer), Anastasia Bodan (Director) (SEC Form D, October 7, 2026).
Selling to Anvion Bio, Inc.? See who runs it and how to reach them, plus this week's 44 other newly funded companies.
Is this your company?
Sell to companies like Anvion Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-07 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Anvion Bio, Inc.
Free to see. No signup.
More on the people and the money behind Anvion Bio, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Anvion Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Anvion Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Anvion Bio, Inc. →Get the full cited report on Anvion Bio, Inc.
What the filing shows about Anvion Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Anvion Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Anvion Bio, Inc.'s address as 6191 Cornerstone Court E., Suite 109, San Diego, CA 92121.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Anvion Bio, Inc. is a registered filer with the SEC (CIK 2158000) and has filed since 2026-10-07. 1 filing is on record, the latest on 2026-10-07.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Anvion Bio, Inc.'s Form D of 2026-10-07 names Larry Braga, Kevin Ernst and Anastasia Bodan as its officers, directors or promoters.
Its new offerings report $100K sold across 1 offering, as its own filings state.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $100K, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Larry Braga is named as Chief Executive Officer and Secretary on the Form D that Anvion Bio, Inc. filed with the SEC on 7 October 2026, one of 3 people that filing names.
On the filing as: Executive Officer, Director.
Kevin Ernst is named as Chief Financial Officer on the Form D that Anvion Bio, Inc. filed with the SEC on 7 October 2026, one of 3 people that filing names.
Anastasia Bodan is named as Director on the Form D that Anvion Bio, Inc. filed with the SEC on 7 October 2026, one of 3 people that filing names.
3 people named on the filing — 2 holding an executive role and 1 as a director only.
Named as of the 2026-10-07 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Anvion Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Anvion Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Anvion Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Anvion Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Anvion Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Anvion Bio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/anvion-bio-inc-form-d-046112